Case Report

Large Cell Neuroendocrine Carcinoma of the Bladder with Adenocarcinomatous Component

Rami Halabi,1,2 Maher Abdessater,1,2 Johnny Boustany,1,2 Anthony Kanbar,1,2 Halim Akl,1,2 Joey El Khoury,1,2 Charbel El Hachem,1,2 and Raghid El Khoury1,2

1Department of Urology, Notre Dame des Secours University Hospital Center (CHUNDS), Byblos City, Lebanon
2Faculty of Medicine and Medical Sciences, Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon

Correspondence should be addressed to Maher Abdessater; maher.abdessater@gmail.com

Received 3 May 2020; Revised 5 September 2020; Accepted 28 September 2020; Published 6 October 2020

Academic Editor: Tun-Chieh Chen

Copyright © 2020 Rami Halabi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Large cell neuroendocrine carcinoma (LCNC) is one of the rarest types of bladder cancer occurring in <1%. Either pure or mixed with another component, it remains one of the most aggressive types of bladder cancer. We report a case of LCNC of the bladder with an adenocarcinomatous component. The patient was a 64-year-old smoker male, who presented for the first time with dysuria and hematuria. A bladder tumor invading the anterior and right lateral bladder walls was discovered, without any secondary localizations. Tumor biopsy showed an LCNC with adenocarcinomatous components. The patient was treated by recurrent tumor resections, chemotherapy, and radiotherapy. No improvement was noted despite close follow-up and adequate treatment. Neuroendocrine bladder tumor is known to have an aggressive, rapid, and disadvantageous evolution. Multiple case reports were published so far, and a recent review was conducted in March 2020 by Sanguedolce et al. (2020). More cases are needed to establish the best management plan for this type of tumor.

1. Introduction

Bladder cancer (BC) is the 6th most frequent neoplasm in men and the 17th most frequent in women [1]. Its annual incidence increased from 430,000 cases in 2012 to 550,000 in 2018 [1, 2]. Lebanon was found to have the world’s highest rate of BC [1]. According to the World Health Organization classification, more than 90% of BC are urothelial and around 5% are squamous cell carcinoma. The neuroendocrine bladder carcinoma is considered a rare variant (<1%) with highly aggressive potential. These tumors are divided into small cell neuroendocrine carcinoma, large cell neuroendocrine carcinoma, well-differentiated neuroendocrine tumor, and paraganglioma [2]. The small cell type is the most common, and the large cell neuroendocrine cancer type (LCNC) is the rarest. Less than forty cases of LCNC were reported so far in the literature. Only three cases had histological similarities to our case [3–5]. Management strategies are not yet studied prospectively [6, 7]. In this article, we report a case of LCNC with an adenocarcinomatous component.

2. Case Presentation

A 64-year-old heavy smoker male patient was admitted for the first time to our urology department for hematuria and dysuria. His past medical history was unremarkable. He had a transurethral resection of the prostate 5 years ago. He did not have any familial history of urothelial or bladder cancer. Physical examination and blood tests were normal. In the emergency room, an abdominal and pelvic ultrasound showed a thickening of the right lateral wall of the bladder (Figure 1). On cystoscopy, a large tumor was found on the anterior and right lateral walls of the bladder, with invasion of the bladder neck and the prostate. The anatomopathological study of the tumor showed a neoplastic proliferation of large malignant polygonal cells with dark, irregular nuclei and frequent mitosis. A second component made of cylindrical cells was also present. Muscular invasion was documented with multiple necrotic areas (Figure 2). Immunohistochemistry showed high positivity for CD56 marker and synaptophysin, minor
and heterogenic positivity for cytokeratin 7, and negativity for cytokeratin 20 and CDX2 (Figures 3–5). Overall, the histopathological study corresponded to LCNC with minor adenocarcinomatous component. Disease extension was assessed using computed tomography (CT) scan of the thorax, abdomen, and pelvis. A 6×3.5 cm mass of the anterior and right lateral walls of the bladder was identified, with diffuse infiltration of the perivesical fat and multiple necrotic iliac lymph nodes bilaterally (Figure 6). Neither visceral nor bone metastasis was identified. Initially, the patient refused the treatment and was lost to follow-up. Two months later, he was readmitted to the hospital for similar complaints and additional pelvic pain. Blood tests were normal. A new CT scan revealed an increase in the size of the tumor, occupying now the majority of the bladder lumen, a persistent right hydronephrosis, and no new secondary lesions. The tumor was resected again, until the appearance of the muscular layer of the bladder, and the patient was discharged after stabilization. A later PET CT confirmed the previous findings of locoregional disease (tumor of the bladder base with infiltration of the prostate gland and a diffuse metastatic bilateral iliac chain and retroperitoneal lymph nodes) and denied secondary lesions. The multidisciplinary team meeting decided for radiotherapy and chemotherapy using cisplatin and etoposide every 21 days. Four months later, after the completion of four cycles of chemotherapy, the patient underwent new assessment for disease extension (Figure 7). CT scan showed progression of the disease with the tumor occupying now the totality of the bladder lumen, infiltration of the anterior abdominal wall, and subcutaneous liquid collection measuring 33×36 mm. A similar left retrovesical mass of 60×38 mm along with multiple para-aortic and mediastinal lymphadenopathies with central necrosis was also found. A few months later, the patient died in the oncology department after recurrent admissions for different complications.

3. Discussion

Neuroendocrine carcinomas are most frequently seen in the pulmonary and gastrointestinal tracts. This type of tumor can be also found in the urinary tract. According to the literature, different types of neuroendocrine carcinomas of the
bladder were described. The LCNC is the rarest type [8, 9]. It can present as a pure tumor, or in association with carcinosarcoma, adenocarcinoma or lymphoepithelioma-like carcinoma.

The first published case by Abenoza et al. had mixed histological features of LCNC and adenocarcinomatous cells. It was treated by a radical cystectomy and bilateral lymphadenectomy. The patient died 30 months after the surgery [9]. Subsequently, less than forty cases of pure and mixed LCNC were published [3, 4, 6–8, 10–21]. To our knowledge, only three cases showed similar histological characteristics to our case, with LCNC and adenocarcinoma components [7, 17, 22].

Only two of the published cases of LCNC were discovered from cutaneous or a brain metastasis [10, 13]. Our patient presented local infiltration of the prostatic gland with bilateral iliac and retroperitoneal lymph nodes. Although the latter was a frequent finding in the literature, the former has never been described [23].

The clinical presentation of our patient was a typical presentation of bladder cancer, similar to the previously published cases, in which hematuria was a frequent presentation [3–5, 7, 8, 12, 13, 17–19].

No guidelines were ever published concerning the treatment modalities of LCNC. A cisplatin-based chemotherapy consisted the base of the treatment strategies through literature. A multimodal therapeutic approach, using the combination of chemotherapy, radiotherapy, and radical or partial surgeries, has been reported [3, 4, 25, 27]. Dowd et al. reported after the treatment by surgical resection and adjuvant chemotherapy and radiotherapy, no recurrence at one year [4]. In their study in 2018 on thirty-five cases of LCNC, Niu et al. reported higher survival rates in patients treated by multimodal therapies compared to patients treated with a conservative treatment. They reported also that a platine-based chemotherapy was the most used option [28].

The management plan of our patient was similar to Dowd et al.’s plan. Our patient was managed by repetitive transurethral tumor resection of the bladder tumor, multiple cycles of cisplatin and etoposide chemotherapy, and radiotherapy.

Coelho et al. have stated in their case report and review that LCNC has a bad prognosis and is usually discovered in an advanced or metastatic stage [7]. A bibliographic review in 2011 by Martin et al. showed that the survival rate for all published cases concerning LCNC was 46.2% for a maximum follow-up of 20 months [23], which was the case of our patient.

4. Conclusion

Bladder tumor incidence is increasing nowadays. Neuroendocrine type is a rare one, with aggressive, rapid, and disadvantageous evolution. So far, we lack prospective studies concerning therapeutic strategies, and management is based on some previous published case reports.

Conflicts of Interest

All authors declare no conflicts of interest exist.
References


